Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.

ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19) has affected >210 million people worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since the history of cancer was linked to higher mortality rates due to COVID-19, the establishment of a safe and effective vaccine coverage is crucial in these patients. However, patients with cancer (PsC) were mostly excluded from vaccine candidates' clinical trials. This systematic review aims to investigate the current available evidence about the immunogenicity of COVID-19 vaccines in PsC.

Patients and methods

All prospective studies that evaluated the safety and efficacy of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included, with immunogenicity after the first and the

SUBMITTER: Corti C 

PROVIDER: S-EPMC8552625 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature